Groowe Groowe / Newsroom / IONS
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

IONS News

Ionis Pharmaceuticals, Inc. Common Stock

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

businesswire.com
IONS

Form 8-K

sec.gov
IONS

ATTR Early-Career Research Forum Opens National Call for Abstracts; Two $100,000 Wiesman Awards to Be Granted

prnewswire.com
AZN IONS

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

businesswire.com
IONS

New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia USA - English USA - English

prnewswire.com
IONS

New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia

prnewswire.com
IONS

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight

globenewswire.com
IONS ALNY NVS BIIB ARWR SLN WVE VNDA NSP TCRT AMX CDIO SRPT VIR BNTX ARCT GSK PFE

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease

businesswire.com
IONS BIIB

Longwood Healthcare Leaders to Host MIT CEO, Off-the-Record Networking and Discussion Forum, Convening Life Science Thought Leaders at MIT Koch Institute

accessnewswire.com
BIIB ALNY MRNA REGN JNJ BEAM IONS

Ionis to present at upcoming investor conferences

businesswire.com
IONS